Author Archives: pan_admin

Aldagen Acquired by Regenerative Biotherapy Firm Cytomedix

GAITHERSBURG, Md. – Cytomedix, Inc. (OTC/BB: CMXI), a leading developer of biologically active regenerative therapies for wound care,inflammation and angiogenesis, announces the completion of the acquisition of Aldagen, Inc., a privately held biopharmaceutical company developing regenerative cell therapiesbased on its proprietary ALDH bright cell (“ALDHbr”) technology. Under the terms of thetransaction as described below, Cytomedix issued preferred shares valued at $16 millionbased on a 10-day volume-weighted average price (“VWAP”) calculated through February 2,2012. Cytomedix will issue additional consideration to be paid in common stock upon the successful attainment of several clinical milestones. As part of the transaction, certain Aldagen investors purchased $5.0 million of Cytomedix common stock in a private placement concurrent with the closing of this acquisition.

Martin P. Rosendale, Chief Executive Officer of Cytomedix, commented, “Since joining Cytomedix as chief executive in 2008, our strategy has evolved, but the vision to transform the Company from a wound-care based technology platform into a broader regenerative medicine company has remained constant. In pursuit of this vision, we started with the successful 2010 acquisition and integration of the Angel System, a unique, best-in-class PRP platform technology that has allowed us to grow from nominal sales to $6 million per year injust over 18 months.”

“This strategic acquisition of Aldagen provides Cytomedix with a novel, patent-protected cell selection technology that fits well with our existing commercial products and strengthens our long-range growth profile”, he continued. “In combination, we now touch the three pillars of regenerative medicine with autologous stem cells, platelet-derived signal molecules and plasma scaffolds,” he added. “We view the acquisition of Aldagen as an opportunistic transaction at an attractive valuation that will allow us to build and expand our new product development efforts with Aldagen’s technology, intellectual property, people and clinical expertise. In terms of maximizing opportunity for our shareholders while managing and mitigating risk, we feel this transaction is very advantageous.”

Commenting on the acquisition, Richard Kent, M.D., Chairman of the Board of Aldagen and a Partner with Intersouth Partners, Aldagen’s largest shareholder, said, “We are delighted to join forces with Cytomedix as this alignment unites commercial products with a growing revenue stream with a deep pipeline of clinical opportunities. We believe these autologous technologies are complementary and hold potential to produce more therapeutics than either one could on its own. The commitment of additional capital into Cytomedix by certain Aldagen investors underscores our confidence in the very promising potential for the combination of these regenerative technologies to change how we treat a variety of large disease areas with continued unmet medical need.”

Transaction Terms

At the closing, Cytomedix issued 135,398 newly designated Cytomedix Series E preferred shares to Aldagen shareholders. Pro forma for the conversion of these shares to common stock, as set forth in the designations documents for the Series E preferred stock, Aldagen shareholders will own approximately 17.3% of Cytomedix common shares outstanding after the concurrent conversion and/or redemption of all existing Cytomedix preferred shares.

There are also contingent clinical milestone payments totaling up to 20,309,723 shares, which will be issued to Aldagen shareholders upon the achievement of predetermined clinical milestones associated with an ongoing Aldagen Phase 2 trial in post-acute ischemic stroke. Notably, 80% of this contingent consideration is issuable only upon a favorable clinical efficacy signal in the above-mentioned trial. The costs of the clinical trial will be funded, in part, by the $5.0 million investment made by Aldagen shareholders, $3.0 million in proceeds from completed or committed warrant exercises by existing Cytomedix shareholders, as well as a portion of Cytomedix’ cash on hand. All upfront and contingent consideration shares are subject to lockup restrictions ranging from six to 18 months.

As part of the transaction, as of the closing date three Aldagen Board members have joined the Cytomedix Board, which has been expanded to nine seats. They are Richard Kent, M.D., Chairman of the Board of Aldagen, Lyle Hohnke, Ph.D., Aldagen’s former CEO, and Joseph Del Guercio, Managing Director of CNF Investments and a current Board Observer for Aldagen. Concurrent with these additions, Craig Mendelsohn has stepped down from the Cytomedix Board.

In addition, Edward L. Field, Aldagen’s Chief Operating Officer, has been appointed as Chief Operating Officer of Cytomedix. Aldagen is now a wholly owned subsidiary of Cytomedix and will retain manufacturing and product development facilities in Durham, N.C. For additional information about this transaction, please refer to the Company’s Report on Form 8-K, filed with the Securities and Exchange Commission on or about February 8, 2012.

About Aldagen

Aldagen is a clinical-stage biopharmaceutical company developing patent-protected autologous cell-based therapeutics for tissue repair and regeneration. Aldagen’s clinical development efforts are led by a team of leading researchers and experienced clinicians. All product candidates target conditions with significant unmet medical needs. Aldagen has a deep product pipeline and data generated in a number of disease states including:

  • ALD-301 for the treatment of peripheral arterial disease (“PAD”) and critical limb ischemia (“CLI”)
  • ALD-201 for the treatment of ischemic heart failure
  • ALD-401 for the treatment of ischemic stroke

Safety has been demonstrated in more than 70 patient treatments across all clinical trials of ALDHbr cells and positive study results in CLI and cardiac ischemia have been published and presented at major medical meetings. A growing body of scientific data validates Aldagen’s proprietary technology, including approximately 250 peer-reviewed publications and presentations. Aldagen has the only stem cell selection technology utilizing an intracellular enzyme marker to fractionate essential regenerative cells from bone marrow.

Aldagen’s proprietary bone marrow fractionation process identifies and isolates metabolically active cells expressing high levels of the enzyme aldehyde dehydrogenase, or ALDH, which is a key enzyme involved in the regulation of gene activities associated with cell proliferation and differentiation. The selected biologically instructive cells, ALDHbr cells, have the potential to promote the repair and regeneration of multiple types of cells and tissues, including the growth of new blood vessels, which is critical to the generation of healthy tissue. Preclinical research suggests that ALDHbr cells specifically migrate to sites of ischemic damage and induce the formation of new blood vessels at those sites. In human clinical trials utilizing ALDHbr cells, evidence of improved perfusion in ischemic tissue has been observed. Other stem cell therapies require expansion of cells that increase manufacturing and regulatory risk, increase processing costs and may delay treatment of the patient up to several weeks. Aldagen produces well-characterized cell populations with a high level of purity without the need for these additional steps, thereby enabling a rapid turnaround time – typically 36 hours once the bone marrow is received.

Opus National Capital Markets served as financial advisor and Cozen O’Connor served as legal counsel to Cytomedix on the acquisition. The Merchant Banking Group of Burrill & Company served as financial advisor and Hutchison Law Group served as legal counsel to Aldagen, Inc. on the transaction.

About Cytomedix, Inc.

Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of autologous platelet rich plasma (“PRP”) gel for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma (“PPP”) and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Additional information regarding Cytomedix is available at


Phthisis Diagnostics Wins Over $500,000 in Virginia Grant Awards

Charlottesville-based Phthisis Diagnostics, Inc. has been awarded over half a million dollars in a combination of grants from the Commonwealth of Virginia.  Phthisis will receive a Commercialization Program grant of $499,477 and a Small Business Innovation Research (SBIR) Matching Funds award for $49,400 (total of $548,877) through the Commonwealth Research Commercialization Fund (CRCF).

On Wednesday, Virginia’s Center for Innovative Technology (CIT) announced that the company was one of 22 Virginia organizations to receive a total of over $3.6 million in funding for a variety of projects to support innovation and business growth in the state.  The bid solicitation generated more than 90 eligible proposals for over $21 million in requested funding spanning a range of industries identified as priority areas for the Commonwealth.  Phthisis Diagnostics received one of only four grants awarded in the Commercialization Program.  Two other Charlottesville-based companies, Hemoshear, LLC and Retivue, LLC, also received Commercialization Program awards.  According to Crystal Icenhour, PhD, President and Chief Science Officer of Phthisis Diagnostics, “This funding will support development and launch of two molecular diagnostic kits that will fulfill a critical need for better diagnosis of intestinal parasites.  We are honored to receive this commercialization support from the Commonwealth of Virginia.”  Phthisis sought the grant   funding to facilitate itsCommercialization of Cryptosporidium/Giardia Molecular Diagnostic. Companies developing new technology often find it somewhat easier to secure research funding than to develop the resources that will enable them to bring their product to market.  Commercialization grants fill an important gap, especially for small, innovative firms.

Infectious disease is the fourth leading cause of death in the United States and the leading cause of death worldwide.  Quickly identifying and targeting the disease with appropriate intervention can save lives and healthcare costs on a massive scale.  Molecular diagnostic technology is a quicker and more accurate method for identifying the pathogen responsible for a patient’s illness.

About Phthisis Diagnostics

Phthisis Diagnostics, founded in 2005, is a rapidly growing biotechnology company developing the Simply Molecular® product catalog, a range of innovative molecular diagnostic products designed for speed, accuracy, and ease of use.  The SimplyMolecular® catalog offers solutions for DNA Extraction, Molecular Diagnostics, and Laboratory Quality Control.

The company launched its first product in May 2011 with the E-Sphere™ Stool DNA Extraction Kit.  Such an extraction process from a specimen must be done before any diagnostic process can proceed.  Laboratories have expressed their need for a faster, simpler method to purify genomic DNA from human stool samples prior to their full analysis to determine the exact disease causing a patient’s symptoms.  Faster speed not only allows the lab to achieve greater efficiency in processing samples, but it also plays an important role in getting effective treatment started as quickly as possible.  Faster, effective treatment of infections can be life saving, especially when the patient is an infant or elderly patient.

The E-Sphere™ Stool DNA Extraction Kit answers the market need for speed with the added benefits of accuracy, greater cost effectiveness, reduced risk of sample contamination, and improved safety for lab technicians.  The process requires only standard clinical laboratory equipment.

For more information about Phthisis Diagnostics, please visit


About Crystal Icenhour, PhD

In 2006, Crystal Icenhour, PhD, became President and Chief Science Officer for Phthisis Diagnostics, located in Charlottesville, VA.  She is also an adjunct assistant professor at Duke University Medical Center’s Division of Infectious Diseases in their
Department of Medicine.  She has demonstrated business leadership in addition to her scientific capabilities and has expressed a goal of “bridging the translational gap between these two worlds.”

Dr. Icenhour has authored seven patents, has authored and co-authored 14 research articles, and has been a prolific speaker and presenter at scientific conferences.  She has served on review panels for the National Science Foundation and Environmental Protection Agency Small Business Innovation Research (SBIR) grants.  Dr. Icenhour currently serves on the board of the Virginia Biotechnology Association and on the editorial board for the Journal of Microbiological Methods. She is a member of the Charlottesville Business Innovation Council, Sigma Xi, Medical Mycology Society of the Americas, National Postdoctoral Association, and the American Society for Microbiology.

About Molecular Diagnostics

Innovations in molecular diagnostics have increased with the growth in understanding of the human genome and how DNA and RNA function at the molecular level. As understanding has increased, so has the demand for the development of molecular
diagnostic methods for improving sensitivity and speed. With increased demand by hospitals and clinical laboratories for molecular diagnostics to improve diagnosis, innovations have led to new products and kits that increase the reliability and speed. The ultimate goal is fast and accurate diagnosis to improve patient outcomes.

Hospitals and diagnostic laboratories are turning to molecular diagnostic methods to guarantee the highest levels of reliability and the greatest speed. Reliability is essential, because an inaccurate or missed diagnosis can be a matter of life and death. Another issue driving the need for new molecular diagnostics is the ability of microorganisms to evade and even inactivate potent antibiotics, causing health care providers to be faced with substantial infectious disease challenges. The varieties of technologies used in molecular diagnostics have transformed clinical laboratory medicine. Market analysts are predicting a 15% increase in the molecular diagnostic market over the next several years.

About the Commonwealth Research Commercialization Fund (CRCF)

The Commonwealth Research Commercialization Fund (CRCF) advances science- and technology-based research, development, and commercialization to drive economic growth in Virginia and to encourage collaboration among its institutions of higher education and partnerships between these colleges and universities and business and industry.  The General Assembly appropriated $6 million to the Fund for FY2012, with $2 million designated for the Small Business Innovation Research (SBIR) matching program.  Underlying the overall program is the strategy to enhance economic development through technology research and commercialization to successfully bring new ideas to the marketplace.


Bioptigen Awarded Phase II SBIR Grant From National Institutes of Health

RESEARCH TRIANGLE PARK, N.C. – Bioptigen Inc., a medical-device company that has developed innovative ophthalmic imaging technologies for translational research, has been awarded a $2.7 million, 27-month grant from the National Eye Institute of the U.S. National Institutes of Health.

The company will apply the grant to the research of spectral domain optical coherence tomography (SDOCT) systems targeted to the needs of the pediatric population.

“Children have unique eye care needs,” said Dr. Eric L. Buckland, president and CEO of Bioptigen. “It is both exciting and satisfying to work on imaging tailored to the developing eye. Our objective is to provide researchers and clinicians with the comprehensive, mobile imaging they require to properly view and manage pediatric eye disease.”

The National Eye Institute grant was awarded for the investigation of technologies related to portable SDOCT imaging that could be applied to the research, diagnosis and treatment of childhood eye diseases. The goal of this research would be to enable structural and functional imaging of premature and neonatal infants using a compact, hand-held device.

Bioptigen‘s high-performance optical imaging technologies support researchers and clinicians in the study of eye pathologies – equipping them to explore new avenues of understanding to advance disease detection and treatment. The Bioptigen Envisu™ spectral domain ophthalmic imaging platform employs low-power incoherent light to generate high-resolution, depth-resolved images of ocular tissues. Envisu rapidly acquires and displays volumetric images suitable for real-time exploration of tissue physiology and pathology.

Bioptigen systems are deployed in nine of the top 10 ophthalmic research institutions in the country.

Bioptigen‘s innovations are covered by more than 60 patent applications, including 30 awarded patents. Researchers and clinicians have published more than 100 scientific articles supported by data acquired in the use of the company’s technologies.


Fall 2011 ACA Southeast Regional Meeting, Charlotte, NC

Join with members of ACA Groups from across the Southeast at the fall 2011 Southeast ACA regional meeting. This event will provide a great peer exchange and networking for investors. The event begins with a reception on Tuesday, October 18th and the main content on syndication, local investment trends, and exits will be on Wednesday, October 19th.

**Please note that this meeting will be capped at 75 attendees so please sign up soon!**

Date: October 18 & 19

Please go to: to learn more about this event.

The Tech Briefing

Tech Briefing Returns on September 15….Don’t Miss It! The 10th Annual Technology Briefing will be held on September 15 at 8:00 a.m. at the Benton Convention Center in Winston-Salem. This is a chance to learn about some exciting local companies and how their technologies are laying the foundation for future economic growth in our community. This year’s presenters are: Cook Medical; NanoMedica; OnceLogix; Paragon Noise Barriers; SkinDeep FX; Small Footprint/Treks in the City; Stantec; Verbal Victor; and Virginia Tech/WFU School of Biomedical Engineering. It is always an entertaining and insightful event you don’t want to miss! The Tech Briefing is free and open to the public courtesy of the sponsors: Cook Medical; Kilpatrick Townsend Attorneys; Piedmont Angel Network, Targacept and Wake Forest School of Medicine’s Office of Technology Asset Management.

Learn more and register online at

Chamber members and non-members are all invited to attend!


PTP NEXT The Piedmont Triad Business Competition

The PTP NEXT Business Competition is a unique economic development initiative established by PTP NEXT, a region-wide organization of talented young leaders who are committed to the Triad’s future economic vitality. Developed in collaboration with the Piedmont Triad Partnership and NC IDEA, the competition will identify and support high potential entrepreneurial companies that are strategically aligned to our region’s unique assets. The PTP NEXT Business Competition is open to start-up and existing entrepreneurial companies who are, or will be, headquartered in the Piedmont Triad Region. Winners will demonstrate strong potential for growth and job creation based on innovative products, services, processes and/or technologies. Grant of up to $50,000 will be awarded for the first time in November 2011.

For more information or to apply visit:

Batanga, Inc. Completes the Acquisitions of Two Leading Online Media Companies in Latin America

Copyright 2011 PR Newswire. All Rights Reserved

MIAMI, June 7, 2011 /PRNewswire/ — Batanga, Inc. today announced the acquisition of two of the leading Latin American online media companies, Adfunky and I-Network. The new acquisitions will exponentially increase the company’s audience and publishing partners in the US, Mexico and Latin America as well as provide its existing sales organization with value-added product offerings for marketers looking to reach Hispanic consumers online. Headquartered in Miami, regional offices are located in Mexico City, Bogota and Buenos Aires as well as sales offices in nineteen cities throughout the globe. GroupArgent represented Adfunky and I-Network in the transaction and acted as their exclusive financial advisors.

Batanga, Inc. is now the largest independent digital media company serving U.S. Hispanic and Latin American markets. By leveraging investments in technology, product and content, Batanga, Inc. creates significant value for its advertisers and publishers in both markets. These acquisitions represent a major commitment by Batanga, Inc. to the Hispanic online market.

“For almost twelve years, Batanga has consistently delivered the U.S. Hispanic online audience to hundreds of advertisers. These acquisitions will allow us to grow our U.S. Hispanic business as well as deliver audiences in some of the fastest growing emerging online markets in the world,” said Rafael Urbina, Chairman and CEO, Batanga, Inc. “Our commitment to the U.S. Hispanic online market has never been stronger and we are now poised to offer the same quality products throughout Mexico and Latin America.”

Based in Argentina, Adfunky is a fast growing ad network and digital media company founded by Internet veterans to boost the results of advertisers, agencies and publishers. “Uniting Adfunky’s audience and expertise, both in the U.S. and abroad, with Batanga’s sophisticated products will create impactful opportunities for advertisers,” said Mariano Burstein, Co-Founder, Adfunky. “We are thrilled to be part of such an innovative team,” echoed Matias Charas, Co-Founder, Adfunky. “Collectively, we have much more insight and understand Hispanics online better than anyone else.”

I-Network, a Bogota-based online marketing company, is a clear leader in the markets it operates in. “We are eager to join forces with Batanga and work alongside U.S. marketers looking to reach a Latin American audience,” said Juan Carlos Samper, CEO, I-Network. “As the marketplace continues to evolve, Batanga is ready to deliver the Latin consumer in the U.S. and abroad.”

About Batanga, Inc.
Batanga, Inc. is the largest independent digital media company serving the U.S. Hispanic and Latin American markets. Its holdings include Batanga Network,, Adfunky and I-Network. Batanga Network reaches the most U.S. Hispanics online, across all categories and demographics. Adfunky is the fastest growing advertiser-centric ad network and marketing solutions provider in Latin America, while I-Network is the largest, independent digital rep firm and ad network serving the fast growing Andean, Caribbean and Central American markets. Batanga, Inc. maintains offices in Miami, Mexico City, Bogota and Buenos Aires, with sales offices in Cali, Caracas, Chicago, Guatemala, Lima, Los Angeles, Managua, Medellin, New York City, Panama, Quito, San Francisco, San Jose, San Salvador, Santiago, Santo Domingo, Santa Cruz, Sao Paulo and Tegucigalpa. For more information visit

SOURCE Batanga

Sensory Analytics wins 2011 Metpack Innovation Award for SpecMetrix Systems

Greensboro, NC and Essen, Germany (May 18, 2011) – SpecMetrix® systems from Sensory Analytics, LLC have been awarded the prestigious 2011 Innovation Gold Award from an independent and distinguished international jury of experts at the 2011 Metpack Trade Fair in Essen, Germany. The internationally renowned award is given out once every three years to the most innovative and trail-blazing product at Metpack, the world’s leading trade fair for the metal packaging industry. The key selection criteria for the award were the impact of the new offerings on production cost reduction and product quality in the metal packaging industry.

Greg Frisby, Industry Manager of Sensory Analytics said “Sensory is extremely honored that our exclusive SpecMetrix film weight measurement systems for the beverage, food and aerosol markets have been recognized by such an impressive global jury as the most impactful and innovative new offerings for the metal packaging industry. Global metal packaging manufacturers will greatly benefit from the use of SpecMetrix systems for all of their film weight and coating thickness measurement needs.”

SpecMetrix systems have a proven ability to help manufacturers of beverage and food containers, aerosol containers and tubes, coated coils, ends and closures to increase coating quality, reduce production costs and spoilage, and maximize production throughput through the use of Sensory’s exclusive non-contact measurement technologies. All SpecMetrix systems deliver precise, real-time thickness and film weight measurement results on wet or dry coatings while in-process or in the QA lab, with no direct contact with coatings.

In March, 2011, SpecMetrix systems were also named the 2011 Technology of the Year by the Association of International Metallizers, Coaters and Laminators, demonstrating the flexible system designs and broad market appeal of the expanding line of in-process quality assurance and process control offerings from Sensory Analytics.

About Sensory Analytics

Sensory Analytics is a fast-growing leader in the development of cost-saving coating thickness and film weight measurement solutions for coating, converting and process control applications within the global metal and flexible packaging, industrial coating, cleantech, solar and aerospace markets. The company’s exclusive SpecMetrix systems deliver real-time coating measurement and coating process validation of wet or dry coatings and thin films in QA labs or directly within the production process.

For additional information on the company’s cost-saving systems or to explore business development or OEM opportunities that support of the global expansion of SpecMetrix systems, please visit Sensory Analytics at

Bioptigen Unveils Image Analysis Software


NewswireToday – /newswire/ – Research Triangle Park, NC, United States, 04/29/2011 – New software delivers automated retinal layer segmentation of mouse SDOCT images –

Bioptigen, Inc., a medical device company whose innovative ophthalmic imaging technologies produce highly resolved images for researchers and clinicians, has released a new software package, InVivoVue™ Miner.

InVivoVue Miner automates analysis of retinal layers of mouse models acquired in vivo with Bioptigen’s spectral domain optical coherence tomography imaging systems. InVivoVue Miner automatically segments eight discrete layers of the rodent retina; aggregates thickness results into a common ETDRS-like grid; and generates graphical reports, thickness maps and intensity projections of all available layers.

Armed with InVivoVue Miner software, scientists can visualize and quantify findings related to retinal disease progression and therapeutic modalities with a minimum of user intervention.

Dr. Eric Buckland, president and CEO, said that the batch processing functionality of Bioptigen’s new software enables high throughput analysis of large data sets for both prospective and retrospective studies.

“Researchers working within the pre-clinical arena want this software because it advances their ability to quantify, validate and publish results more rapidly and less laboriously than is currently possible with other methods of managing OCT image data,” Buckland said. “By equipping researchers in their quest to better understand early disease progression, Bioptigen continues to open new avenues for biological exploration, monitoring of disease progression, and development of therapeutic interventions.”

Bioptigen will unveil its InVivoVue Miner software at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting taking place May 1-5 in Fort Lauderdale, Fla.

Bioptigen originally created its proprietary non-invasive spectral domain ophthalmic imaging platform – called Envisu™ – specifically for small animal imaging. The Envisu family of imaging systems uses low-power, near-infrared light to acquire, process, display and store real-time, depth-resolved images of ocular tissues. Envisu delivers resolution 100 times finer than standard ultrasound, and is suitable for analyzing tissue microstructure with features as small as two micrometers.

Bioptigen ( delivers highly sophisticated medical imaging devices renowned for their performance and versatility. The company’s passion for collaboration and innovation enables life-changing advances in health care through the boundless potential of its revolutionary imaging technologies.

SpecMetrix Systems from Sensory Analytics Named Technology of the Year


March 25, 2011 11:04 AM Eastern Daylight Time

SpecMetrix Systems from Sensory Analytics Named Technology of the Year

PHOENIX–(BUSINESS WIRE)–SpecMetrix® systems from Sensory Analytics, LLC have been named Technology of the Year by the Association of International Metallizers, Coaters and Laminators at their 2011 Annual Management Meeting. According to the five-member judging panel, “SpecMetrix systems are a major step forward” and predicted that “these new tools will impact an extremely broad segment of the converting industry.”

“these new tools will impact an extremely broad segment of the converting industry.”
.Greg Frisby, Industry Manager of Sensory Analytics said “Sensory is honored that our exclusive SpecMetrix In-line and Lab systems have been recognized by the leading global coating, laminating and metalizing trade association as their Technology of the Year. The proven ability of SpecMetrix systems to help manufacturers and converters reduce their coating related costs while increasing production throughput and quality have helped to drive Sensory’s rapid expansion within these important markets.”

All SpecMetrix systems deliver precise, real-time coating thickness and film weight measurement results with no contact with coatings or substrates. SpecMetrix systems provide a new non-contact and non-radioactive means to measure wet or dry UV coatings, hard coats, adhesives, varnishes, barrier coatings and other finishes on films, coated papers, foils, metals and other substrates and can help to reduce the environmental footprint of manufacturers.

About Sensory Analytics

Sensory Analytics is a fast-growing leader in the development of cost-saving coating thickness and film weight measurement solutions for coating, converting and process control applications within the global metal and flexible packaging, industrial coating, cleantech, solar and aerospace markets. The company’s exclusive SpecMetrix systems deliver real-time coating measurement and process validation of thin films and coatings in QA labs and during coating and production processes.

The company will be exhibiting its award winning systems in Booth # 950 at the upcoming International Converting Expo (ICE) Show, being held April 6-8, 2011 at the OCCC in Orlando, Florida. For additional information on the company’s innovative cleantech offerings or to explore development opportunities in support of the global expansion of SpecMetrix systems, please visit Sensory Analytics at

About the Association of International Metallizers, Coaters and Laminators

AIMCAL is an international, non-profit trade association that represents converters of metallized, coated, and laminated flexible substrates and their suppliers. The expanding group is headquartered in Fort Mill, South Carolina, USA. Information is available on-line at

Sensory Analytics, LLC
Greg Frisby, 336-315-6090
Fax: 336-315-6030